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To evaluate the in vivo antitumor activity of cleistanthin B in Ehrlich's ascites carcinoma (EAC) and
Dalton's ascites lymphoma (DAL) cell lines induced malignant ascites mouse models and DAL cell line
induced solid tumor mouse model. All animals were injected with 2  106 EAC/DAL cells i.p./s.c. to induce
malignant ascites and solid tumor and treated with 5-ﬂuorouracil (5-FU) 20 mg/kg or cleistanthin B for
10 days. Cleistanthin B was given at three doses viz. 25, 50 and 100 mg/kg. The percentage increase in life
span and the overall survival in malignant ascites animals and the tumor volume in solid tumor animals
were measured. The haematological parameters were assessed in all animals before and 2 weeks after
the treatment. Cleistanthin B 50 mg/kg and 5-FU signiﬁcantly prolonged the life span (>25%) of ma-
lignant ascites tumor bearing animals. The overall survival was signiﬁcantly improved by both. Only
cleistanthin B 50 mg/kg signiﬁcantly reduced the elevated WBC counts in EAC tumor bearing animals.
Both 5-FU and cleistanthin B 50 mg/kg reversed the malignancy induced increase in neutrophils and
platelet counts and decrease in lymphocyte counts but not to the normal range. Only 5-FU signiﬁcantly
reduced the solid tumor volume. None of the three doses of cleistanthin B was effective against the solid
tumor. Cleistanthin B has antitumor activity against EAC and DAL tumor mice but it is not as effective as
5-FU. At 50 mg/kg dose cleistanthin B exerts signiﬁcant antitumor activity compared to 25 and 100 mg/
kg dose. Its effect on WBC count is higher and advantageous when compared to 5-FU. But cleistanthin B
in the doses used is not effective against solid tumor.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is one of the leading causes of death worldwide and
the burden is increasing day by day. Though we have a number of
anticancer agents now, adequate control of cancer is still lacking.
Hence there is a persistent demand to develop newer and more
effective anticancer drugs which can help tackle this problem.
The major groups of anticancer drugs such as vinca alkaloids,
taxanes, camptothecins and epipodophyllotoxins which are
currently a part of many standard anticancer regimens areer.edu.in (R. Raveendran).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).derived from plants.1 Cleistanthin B is an arylnaphthalene lignan
lactones glycosides, the major phytoconstituents responsible for
most of the toxicological and pharmacological actions of Cleis-
tanthus collinus, a plant commonly found in the states of south-
ern India.2 Apart from cleistanthin B, plant has cleistanthin A,
collinusin, and diphyllin.3
Cleistanthin B also present in Dysosma versipellis (Berber-
idaceae), a Chinese herb widely used to clear sputum, kill parasites
and treat epidemic encephalitis B and epidemic parotitis,4 and
Hypoestes purpurea (Acanthaceae), a tropical herb eaten as spinach,
used as a poultice for sore eyes.5,6 Cleistanthins A and B were re-
ported to possess hypotensive7 and diuretic8 properties. While
these compounds have no activity on motor function,9 they were
demonstrated to exhibit signiﬁcant antitumor activity.10e14 Most of
the studies about antitumor activity of these compounds are based
on in vitro assays. The GI50 (50% growth inhibition) values are lowerrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
MST ðdaysÞ ¼ Total number of days survived by all animals in the group
Number of animals in the group
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activity on various cancer cell lines by interfering with cell cycle
progression, causing DNA damage and inducing apoptosis.10 While
cleistanthin A has in vivo antitumor activity against Dalton's ascites
lymphoma (DAL) and S-180 sarcoma tumor bearing animals by
prolonging the life span and reducing the tumor volume,11 there is
no report of the in vivo antitumor activity of cleistanthin B so far.
Hence the present study was focused to evaluate the in vivo anti-
tumor activity of cleistanthin B in Ehrlich's ascites carcinoma (EAC)
and DAL cell line induced malignant ascites and solid tumor in
mice.
2. Materials and methods
2.1. Test compound
Cleistanthin B was isolated from the leaves of C. collinus
(Euphorbiaceae) as described in our previous study.15 Taxonomi-
cally identiﬁed plant leaves were collected in the regions of Pon-
dicherry district and it was certiﬁed by Botanical survey of India,
Coimbatore (BSI/SC/5/23/08-09/Tech.241).
2.2. Cancer cell lines
EAC and DAL cell lines (Amala Cancer Research Center, Thrissur,
Kerala) were maintained by weekly intraperitoneal transplantation
of respective tumor cells (2  106 cells per mouse) in stock animals.
2.3. Chemicals
Carboxymethyl cellulose sodium (CMC) (Lobachemie, Mumbai),
phosphate buffered saline (PBS) (Media labs, Mumbai), Diethyl ether
(Thermo Fisher Scientiﬁc India Pvt Ltd, Mumbai) and 5-ﬂuorouracil
(5-FU) (Ceon labs, Andhra Pradesh) were used for the study.
2.4. Instruments
Automated haematology analyzer (SYSMEX XS-1000i; Sysmex
Corporation, Kobe, Japan) was used for the complete blood cell
counts.
2.5. Animals
Female Swiss albinomicewere obtained from the central animal
house of JIPMER, Pondicherry and they were maintained under
standard laboratory conditions throughout the study. The animals
were fed with standard rodent pellet feed (Amrut feeds, Sangli,
India) and water ad libitum. Adult mice weighing 20e30 g were
used for the experiments. The study protocol was approved by the
Institutional Animal Ethics Committee (No: Jip/Micro/Jiaec/2012)
and all the animal experiments were carried out in accordancewith
the guidelines of the Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA), India.
2.6. Study design
An exploratory study was designed to evaluate the in vivo
antitumor activity of cleistanthin B using different mouse tumor
models. Study I and II were carried out with EAC and DAL cell lines
inducedmalignant ascites mousemodels, respectively. DAL cell line
induced solid tumor mouse model was used for study III. Three
doses of cleistanthin B viz. 25, 50 and 100mg/kg were chosen based
on the results of a toxicity study done previously.16 The animals
were divided into ﬁve different groups as follows:Group I: Tumor control
Group II: 5-FU 20 mg/kg
Group III: Cleistanthin B 25 mg/kg
Group IV: Cleistanthin B 50 mg/kg
Group V: Cleistanthin B 100 mg/kg
Study I and II used 8 mice in each group while study III used 6
mice per group. Group I served as a positive (tumor) control (0.5%
CMC orally) and group II as a comparator control (5-ﬂuorouracil
20 mg/kg; i.p.). Groups III, IV and V were given cleistanthin B
orally at the doses of 25, 50 and 100 mg/kg respectively. The study
design is summarized in Fig. 1.2.7. Experimental procedure
On day 1, blood collection from retro-orbital plexus was car-
ried out and the samples (0.3 ml) in EDTA were used for the
assessment of haematological parameters such as haemoglobin
(Hb) content, red blood cell (RBC) count, total white blood cell
(WBC) count, neutrophils (%), lymphocytes (%) and platelet
count. On day 2, tumor ﬂuid was withdrawn from the stock an-
imals for EAC and DAL cell lines and the tumor cell count was
done using Neubauer chamber under the light microscope. The
PBS was added to make a concentration of 1  106 cells in 0.1 ml.
For tumor induction in study I and II, each experimental animal
was injected with 2  106 DAL/EAC cells i.e. 0.2 ml intraperito-
neally. In study III, the solid tumor was induced by injecting s.c.
injection of 2  106 DAL cells in 0.1 ml PBS on right hind limb of
each experimental animal. After 24 h of the tumor cells inocu-
lation, the animals were treated according to their respective
groups once daily for next 10 days. On day 15, the retro-orbital
blood collection was done again for haematological assessment,
if the animal was alive.17 The animals were followed till death or
upto 35 days. The parameters for antitumor activity in study I
and II were recorded as follows:
Determination of the percentage increase in life span (PILS):
It is calculated from the mean survival time (MST) values.18 The
MST for each group was calculated as,For each group,
PILS ð%Þ ¼ ½ðMST of treated group=MST of control groupÞ  1  100
Determination of the overall survival: It was based on the
results of survival analysis. In studye III, the antitumor activity was
assessed by the reduction of solid tumor volume.
Determination of the solid tumor volume: The solid tumor
volume was measured on the seventh day after tumor inoculation
and then it was repeated every ﬁfth day until the end of the study.
The tumor volume was calculated using the following formula19
Tumor volume ðmlÞ ¼ 4=3pr21r2

cm3

where, r1 and r2 are two perpendicular radii of the solid tumor
measured using a vernier caliper.
The haematological parameters of all surviving animals such as
haemoglobin, RBC, WBC, neutrophils, lymphocytes and platelets
were assessed for all the three studies. A group of six normal mice
was studied for assessing their haematological parameters. These
normal (control) values were used for comparisons. The tumor
bearing animals alive at the end of the study were sacriﬁced by
cervical dislocation.
Fig. 1. Study plan.
Fig. 2. Effect of cleistanthin B on percentage increase in life span of Ehrlich's ascites
carcinoma (EAC) and Dalton's ascites lymphoma (DAL)tumor bearing mice (n ¼ 8 in
each group, #Signiﬁcant increase (>25%) in PILS compared to tumor control).
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The survival analysis was done by Log-rank test using SPSS
version 20 software package (IBM SPSS, USA). The mean survival
time, haematological parameters and tumor volume comparison
between groups were analyzed using Instat version 3.06 (GraphPad,
USA). The statistical tests used were one-way ANOVA and Krus-
kaleWallis test. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. The antitumor activity of cleistanthin B against malignant
ascites tumor bearing animals
3.1.1. Effect on the survival
Cleistanthin B 50 mg/kg and 5-FU signiﬁcantly increased the
PILS. While 5-FU increased the life span of EAC and DAL animals by
40.6% and 65.1% respectively, cleistanthin B increased it by 25.5%
and 26.2% respectively (Fig. 2). Only cleistanthin B 50 mg/kg and 5-
FU signiﬁcantly improved the overall survival of EAC and DAL tu-
mor bearing animals. While cleistanthin B 50 mg/kg and 5-FU were
not signiﬁcantly different from each other in improving the overall
survival of EAC animals, 5-FU was signiﬁcantly more effective than
all the three doses of cleistanthin B in improving the overall sur-
vival of DAL animals (Fig. 3A and B).
3.1.2. Effect on the haematological parameters
The haematological parameters could not be analyzed in DAL
animals because only four out of 40 animals were alive on day 15.All four animals were in 5-FU group. So mortality was less in 5-FU
group compared to all the three doses of cleistanthin B. The Hb and
RBC count were lower in all the treatment groups compared to
normal control group. TheWBC counts were signiﬁcantly increased
in tumor control, 5-FU and cleistanthin B 25 mg/kg group
compared to normal control group. Only cleistanthin B 50 mg/kg
Fig. 3. Effect of cleistanthin B on the overall survival of EAC (A) and DAL (B) tumor
bearing mice (n ¼ 8 in each group). #P < 0.01, ##P < 0.001 compared to tumor control.
$P < 0.05, $$P < 0.01,$$$P < 0.001 compared to 5-FU.
Fig. 4. : Effect of cleistanthin B on the tumor volume of DAL solid tumor bearing mice.
n ¼ 6 in each group; #P < 0.001 compared to tumor control, when area under the
curves were compared between groups.
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increased and lymphocytes were decreased signiﬁcantly in all the
treatment groups. The platelet count was signiﬁcantly increased in
tumor control and cleistanthin B 25 mg/kg group compared to
normal group (Table 1).Table 1
Effect of cleistanthin B on haematological parameters of EAC tumor bearing mice on day
Group Treatment Hb (g/dl) RBC (1  106/ml) WBC
0 Normal control 14.0 ± 0.23 9.27 ± 0.25 6.20
I Tumor control 9.5 ± 1.44 6.39 ± 1.02 75.73
II 5-FU 20 mg/kg 8.7 ± 1.26* 5.05 ± 0.71** 56.92
III Cleistanthin B 25 mg/kg 8.1 ± 0.10* 5.42 ± 0.71* 34.01
IV Cleistanthin B 50 mg/kg 9.3 ± 0.46* 6.20 ± 0.30 11.77
Hb: Hemoglobin; RBC: Red Blood Cells; WBC: Wight Blood Cells, 5-FU: 5-Fluorouracil.
The values are expressed as mean ± SEM; n ¼ 6 in group 0 and IV, n ¼ 5 in group II, n ¼
*P < 0.05, **P < 0.01, ***P < 0.001 compared to normal control; #P < 0.05 compared to t
The data for cleistanthin B 100 mg/kg group is not included because only one animal w3.2. The antitumor activity of cleistanthin B against solid tumor
bearing animals
All animals with solid tumor survived beyond 35 days.
3.2.1. Effect on the tumor volume
The tumor volume was found to be signiﬁcantly less only in 5-
FU group compared to tumor control group. None of the three
doses of cleistanthin B signiﬁcantly reduced the solid tumor vol-
ume (Fig. 4).
3.2.2. Effect on the haematological parameters
There was no signiﬁcant difference between the groups with
regards to haematological parameters (Data not shown).
4. Discussion
In the present study, cleistanthin B showed signiﬁcant anti-
tumor activity against EAC and DAL cell line induced malignant
ascites tumor animals at 50 mg/kg dose while no signiﬁcant anti-
tumor activity was recorded against DAL solid tumor animals with
all the three doses of cleistanthin B. Even the higher dose of cleis-
tanthin B was found to be less effective than 5-FU which was used
as a standard comparator.
The life span was prolonged by cleistanthin B more than 25% in
both EAC and DAL tumor animals. Prolongation of life span is a
valuable criterion for initial evaluation of antitumor activity of a
new compound.20,21 If the compound increases the life span by 25%,
it can be considered to have a signiﬁcant antitumor activity.22 The
results of survival analysis should also be considered for assessing
the antitumor activity and cleistanthin B has improved the overall
survival of animals. There is no previous report on the in vivo15.
(1  103/ml) Neutrophils (%) Lymphocytes (%) Platelets (1  103/ml)
± 0.48 13.3 ± 1.41 88.2 ± 1.14 683.3 ± 32.18
± 25.17* 83.5 ± 3.75* 13.0 ± 3.58** 1128.0 ± 77.30**
± 12.21** 88.4 ± 2.11** 10.6 ± 1.78*** 794.8 ± 51.83
± 4.26* 78.8 ± 2.87* 21.3 ± 2.87* 955.0 ± 74.53*
± 2.78#$ 67.8 ± 7.35* 31.8 ± 7.28* 835.7 ± 20.54
4 in group I and III.
umor control; $P < 0.05 compared to 5-FU.
as alive on day15.
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tanthins A and B have reported the same. The antineoplastic ac-
tivity was predicted in silico for both the compounds by PASS
bioinformatics tool2 and cleistanthin A which has been evaluated
in vivo in DAL tumor animals was reported to have signiﬁcant
antitumor activity.11 Since cleistanthins A and B are structurally
similar, it is not surprising that cleistanthin B shares the same
in vivo effect.
While cleistanthin B 50 mg/kg signiﬁcantly decreased the WBC
count in EAC tumor animals, 5-FU could not do so. The agents with
antitumor activity tend to decrease the WBC count and it is a
reliable criterion of their antineoplastic activity.23 The increase in
WBC count in tumor bearing animals was probably due to myeloid
leukemoid reaction secondary to malignancy. The signiﬁcant in-
crease inWBC countmay be a defensivemechanism towards tumor
cells. The antitumor effect of a compound will reduce the tumor
cells and decrease theWBC count. The reduction in leucocyte count
probably reﬂected the decrease in tumor burden as well as the
action of compound on the bone marrow precursors. Palanisamy
et al. reported that ﬁshes exposed to C. collinus extract developed
leucopenia.24 The haematological parameters in solid tumor ani-
mals were not deranged. Although 5-FU showed a marginal
decrease in theWBC count, it was not signiﬁcant while cleistanthin
B maintained a near normal range. So it can be said that 5-FU re-
duces the WBC count when it is raised due to malignancy and also
when it is in normal range. In contrast, cleistanthin B reduces WBC
count only when it is raised due tomalignancy and not when it is in
normal state which is advantageous.
The haemoglobin and RBC values were less in all treatment
groups. It is well known that development of anemia is a problem
with most of the cancer chemotherapy agents. In the present study
also we found the same problem with 5-FU and cleistanthin B. The
most common cause of anemia in cancer is chemotherapeutic agent
induced myelosuppression. The anemia in ascites carcinoma
bearing mice can also occur due to iron deﬁciency or haemolytic
conditions. It is known that neutrophils and platelet counts in-
crease while lymphocytes decrease in all the ascites tumor bearing
animals.25 Reactive neutrophilic leucocytosis is known in malig-
nancy and the agents with antitumor activity tend to reverse it.
Both 5-FU and cleistanthin B reversed the deranged neutrophils (%),
lymphocytes (%) and platelet counts but not to the normal range.
Cleistanthin B did not signiﬁcantly reduce the tumor volume in
solid tumor animals. It was reported that cleistanthin B has afﬁnity
towards the localized solid tumor and it may be helpful in the
treatment of solid tumor.26 But in the current study, we did not
observe the beneﬁcial effect of cleistanthin B in solid tumor ani-
mals. Cleistanthin B doses were chosen based on the results of a
previously carried out toxicological study in animals.16,27 It is
possible that the doses selected could have been inadequate against
solid tumor. This is evidenced by the fact that the tumor volume
starts increasing rapidly after stopping the treatment. So cleistan-
thin B given at a higher dose for longer duration might have been
effective against solid tumor.
Out of all the three doses of cleistanthin B only 50 mg/kg has
shown a signiﬁcant antitumor activity in malignant ascites tumor
bearing animals. While cleistanthin B 25 mg/kg dose may be inef-
fective because it did not signiﬁcantly improve the survival of an-
imals, cleistanthin B 100 mg/kg might have exerted toxic effect on
the EAC and DAL tumor bearing animals because most of the ani-
mals in this group died early.
5. Limitations
Parameters such as viability testing of tumor cells and per-
centage cell growth inhibition were not evaluated in our study.Early death of ascites tumor animals did not allow us to collect
blood on day 15. Reducing the initial load of tumor cells to 1  106
cells during inoculation might have helped to circumvent the
problem. We have not carried out the tumor growth delay assay in
solid tumor model which could be done by measuring the tumor
volume every day. These limitations have not affected the outcome
of the study but eliminating them would have given more
information.6. Conclusions
From the present study it can be concluded that cleistanthin B at
the dose of 50 mg/kg has signiﬁcant antitumor activity against EAC
and DAL ascites tumor bearingmice but it is not as effective as 5-FU.
Cleistanthin B has a better effect on WBC count compared to 5-FU
but it has no antitumor activity against solid tumor.Conﬂict of interest
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